

Supplementary table 1. Phase III studies of oxaliplatin-based preoperative chemoradiotherapy

Authors, year of published	Studies	CRT regimen	Patients	Eligible patients	Dose of chemotherapy (mg/m2)	cycles	ypCR (%)	Grade3/4 toxicity (%)
Aschele 2011	STAR-01	5FU/LV +1-OHP	368	cT3/4, N0-2	5-FU: 225×5 1-OHP : 60	6	17	24
G'erard 2012	ACCORD 12/0405	Cape +1-OHP	291	cT3/4, N0-2	Cape: 800×5 1-OHP: 50	5	19	25
Schmoll 2014	PETACC-6	Cape +1-OHP	537	cT3/4, N0-2	Cape: 1650 1-OHP: 50	5	14	38
Allegra 2015	NSABP R-04	Cape +1-OHP or 5FU/LV +1-OHP	659	cT3/4, N0-2	5-FU: 225×5 or Cape: 825×5 1-OHP : 60	5	21	27
Rodel 2015	CAO/ARO/AIO-04	5FU/LV +1-OHP	451	cT3/4, N0-2	5-FU: 250 (d1-14, 22-35) 1-OHP : 50	4	20	20
Deng 2016	FOWARC	5FU/LV +1-OHP	165	cT3/4, N0 T1-4, N1-2	5-FU: 400 (bolus) 5-FU : 2400 (continuous) 1-OHP : 85	5	28	19% hematological 20% nonhematological

Supplementary table 2. Phase II studies of CPT-11-based preoperative chemoradiotherapy

Authors, year of published	CRT regimen	Patients	Eligible patients	Dose of chemotherapy (mg/m2)	cycles	ypCR (%)	Grade3/4 toxicity (%)
single arm Phase II							
Mehta VK 2003	5FU/LV + CPT-11	32	cT3, N0-1	5-FU: 1400 CPT-11: 50	5FU: 5 CPT-11: 4	37%	28%
Navarro M 2006	5FU/LV + CPT-11	74	cT3/4, N0-2	5-FU: 1125 CPT-11: 50	5	14%	15% hematological 14% nonhematological
Willeke F 2007	Cape + CPT-11	36	cT3/4, N0-2	Cape: 1000 CPT-11: 50	5	15%	25%
Shin SJ 2010	S-1 + CPT-11	43	cT3/4, N0-2	S-1: 70 CPT-11: 40	5	21%	23%
Sato T 2011	S-1 + CPT-11	67	cT3/4, N0-2	S-1: 80 CPT-11: 80	4	35%	9%
Hong YS 2011	Cape + CPT-11	48	cT3/4, N0-2	Cape: 1650 CPT-11: 40	5	25%	15.0%
Gollins S 2011	Cape + CPT-11	107	cT3/4, N0-2	Cape: 1300 CPT-11: 60	Cape: 5 CPT-11: 4	22%	22%
Randomized Phase II							
Wong SJ 2015	Cape + CPT-11 Cape + I-OHP	52 52	cT3/4, N0-2	Arm 1: Cape: 1200 CPT-11: 50 Arm 2: Cape: 1650 I-OHP: 50	Arm 1: 4 Arm 2: 5	10% 21%	27% 27%
Jung M 2015	5FU/LV S-1 + CPT-11	66 67	cT3/4, N0-2	Arm 1: 5-FU: 1200 Arm 2: S-1: 70 CPT-11: 40	Arm 1: 2 Arm 2: 5	16% 25%	1% 7%